中外对话：聚焦 Trop-2 ADC 安全性管理，看 PRIMED 研究提供解决方案

文章预览

本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面 ✩ 本文仅供医疗卫生等专业人士参考 参考文献 [1]Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial.2024 ASCO 1101. [2]MedSIR. Multicenter, Open-Label, Single Arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan’s Tolerance in Patients With Metastatic Triple-Negative Breast Cancer. clinicaltrials.gov; 2024. Accessed January 1, 2024. https://clinicaltrials.gov/study/NCT05520723 [3]Bardia A, Rugo HS, Tolaney SM, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by HER2 and Trop-2 Expression. J Clin Oncol. 2022;40(suppl 16):1071 [4]]Evandro de Azambuja, Flavia Jacobs, Matteo Lambertini et al. Relationship of Diarrhea and N ………………………………